We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lilly (LLY) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
In its upcoming report, Eli Lilly (LLY - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $5.38 per share, reflecting a decline of 23.4% compared to the same period last year. Revenues are forecasted to be $22.11 billion, representing a year-over-year increase of 25.6%.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Lilly metrics that Wall Street analysts commonly model and monitor.
The average prediction of analysts places 'Revenue- Cyramza (Ramucirumab /IMC-1121B)- Total' at $202.04 million. The estimate indicates a change of -17.7% from the prior-year quarter.
The consensus estimate for 'Revenue- Humulin' stands at $159.52 million. The estimate indicates a year-over-year change of -9.7%.
The collective assessment of analysts points to an estimated 'Revenue- Jardiance (Empagliflozin/BI 10773)- Total' of $865.61 million. The estimate indicates a year-over-year change of -9.7%.
Analysts forecast 'Revenue- Immunology' to reach $1.54 billion. The estimate indicates a change of +12.8% from the prior-year quarter.
The consensus among analysts is that 'Revenue- Cyramza (Ramucirumab /IMC-1121B)- US' will reach $90.32 million. The estimate indicates a change of -20% from the prior-year quarter.
It is projected by analysts that the 'Revenue- International- Humulin' will reach $51.46 million. The estimate points to a change of -5.8% from the year-ago quarter.
Analysts expect 'Revenue- Trulicity (Dulaglutide / GLP-1 Fc / LY2189265)- US' to come in at $515.15 million. The estimate points to a change of -27.1% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Trulicity (Dulaglutide / GLP-1 Fc / LY2189265)- ROW' will likely reach $300.54 million. The estimate indicates a change of -12.9% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenue- Jardiance (Empagliflozin/BI 10773)- US' should arrive at $415.72 million. The estimate points to a change of -2% from the year-ago quarter.
Analysts predict that the 'Revenue- Jardiance (Empagliflozin/BI 10773)- ROW' will reach $449.89 million. The estimate indicates a change of -15.9% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- ROW' should come in at $208.07 million. The estimate suggests a change of +2.8% year over year.
Shares of Lilly have experienced a change of +7.6% in the past month compared to the -1.2% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), LLY is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Lilly (LLY) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
In its upcoming report, Eli Lilly (LLY - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $5.38 per share, reflecting a decline of 23.4% compared to the same period last year. Revenues are forecasted to be $22.11 billion, representing a year-over-year increase of 25.6%.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Lilly metrics that Wall Street analysts commonly model and monitor.
The average prediction of analysts places 'Revenue- Cyramza (Ramucirumab /IMC-1121B)- Total' at $202.04 million. The estimate indicates a change of -17.7% from the prior-year quarter.
The consensus estimate for 'Revenue- Humulin' stands at $159.52 million. The estimate indicates a year-over-year change of -9.7%.
The collective assessment of analysts points to an estimated 'Revenue- Jardiance (Empagliflozin/BI 10773)- Total' of $865.61 million. The estimate indicates a year-over-year change of -9.7%.
Analysts forecast 'Revenue- Immunology' to reach $1.54 billion. The estimate indicates a change of +12.8% from the prior-year quarter.
The consensus among analysts is that 'Revenue- Cyramza (Ramucirumab /IMC-1121B)- US' will reach $90.32 million. The estimate indicates a change of -20% from the prior-year quarter.
It is projected by analysts that the 'Revenue- International- Humulin' will reach $51.46 million. The estimate points to a change of -5.8% from the year-ago quarter.
Analysts expect 'Revenue- Trulicity (Dulaglutide / GLP-1 Fc / LY2189265)- US' to come in at $515.15 million. The estimate points to a change of -27.1% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Trulicity (Dulaglutide / GLP-1 Fc / LY2189265)- ROW' will likely reach $300.54 million. The estimate indicates a change of -12.9% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenue- Jardiance (Empagliflozin/BI 10773)- US' should arrive at $415.72 million. The estimate points to a change of -2% from the year-ago quarter.
Analysts predict that the 'Revenue- Jardiance (Empagliflozin/BI 10773)- ROW' will reach $449.89 million. The estimate indicates a change of -15.9% from the prior-year quarter.
Analysts' assessment points toward 'Revenue- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- US' reaching $66.40 million.
According to the collective judgment of analysts, 'Revenue- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- ROW' should come in at $208.07 million. The estimate suggests a change of +2.8% year over year.
View all Key Company Metrics for Lilly here>>>Shares of Lilly have experienced a change of +7.6% in the past month compared to the -1.2% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), LLY is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .